Presentation Abstract

Session: Medical, Neuro-Oncology and Epidemiology
Abstract Number: NO-55
Title: Subgroup and quality of life analyses of the phase III clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma
Presentation Start: 11/19/2010 1:00:00 PM
Presentation End: 11/19/2010 1:15:00 PM
Authors: Zvi Ram1, Philip H. Gutin2, Roger Stupp on behalf of the EF-11 study investigators3
1Tel Aviv Medical Center, 2Memorial Sloan Kettering Cancer Center, 3CHUV Lausanne
Category: Medical and Neuro Oncology
Educational Objective 1: 7. Use advances in pharmacology, experimental therapeutics, and radiobiology to improve future therapies for patients with CNS tumors
Abstract: Background:
NovoTTF is a portable device delivering low intensity, intermediate frequency, electric fields using noninvasive, disposable scalp electrodes. These fields physically interfere with cell division. Preliminary studies in recurrent and newly diagnosed GBM have shown promising results. A phase III study in recurrent GBM has recently been concluded.
Methods:
Adults (KPS≥70%) with recurrent GBM (any recurrence) were randomized (stratified by surgery and center) to either NovoTTF administered continuously (20-24h/day, 7 days/week), or the best available chemotherapy (best physician choice - BPC). Primary endpoint was overall survival (OS). PFS6, 1-year survival, and QOL were secondary endpoints.
Results:
237 pts were randomized (28 centers in USA & Europe) to either NovoTTF alone (120 pts) or BPC (117 pts). Patient characteristics were balanced, median age was 54 years (range 23-80), median KPS 80% (50-100). One quarter had surgery for recurrence and over half were at their second or more recurrence. A survival advantage for the device group was seen in patients treated according to protocol (median OS 7.8m vs. 6.1m; n=185; p=0.01). Moreover, subgroup analysis in patients with better prognostic baseline characteristics (KPS≥80%, age≤60, 1st-3rd recurrence) demonstrated a robust survival benefit for NovoTTF patients compared to matched BPC patients (median OS 8.8m vs. 6.6m; n=110; p<0.01). In this group, 1-year survival was 35% vs. 20% and PFS6 was 25.6% vs. 7.7%. Interestingly, in patients who failed Bevacizumab prior to the trial, OS was also significantly extended by NovoTTF (4.4m vs. 3.1m; n=23 vs. n=21; p<0.02). Quality of life was equivalent or superior in NovoTTF patients.
Conclusions:
NovoTTF, a non-invasive, novel cancer treatment modality shows significant therapeutic efficacy with improved quality of life. The impact of NovoTTF was more pronounced when patients with better baseline prognostic factors were treated. A large scale phase III clinical trial in newly diagnosed GBM is currently being conducted.



Technical Support
Phone: 217-398-1792
Helpdesk